[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100317156":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":43,"centralContacts":48,"locations":57,"responsibleParty":78,"collaborators":80,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":10,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":10,"enrollmentInfo":92,"targetDuration":10,"studyType":95,"phases":10,"briefSummary":96,"conditions":97,"keywords":10,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Oncology Institute of Southern Switzerland","OTHER",[8,14,18,22,26,30,34],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 0 (set-up)",null,"Patients with known diagnosis of CSPC (Group 0a) and CRPC (Group 0b) irrespective of the PC treatment (not first diagnosis)",[13],"Other: biological samples collection and analysis",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 1a (control)","Patients who underwent biopsies for suspected Prostate Cancer (PC), with a negative result for invasive cancer",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group 1","Patients with a first diagnosis of localized biopsy-proven PC, untreated, planned to undergo radical surgery and \u002F or radical radiotherapy",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Group 2","Patients with a diagnosis of locally advanced unresectable, recurrent or metastatic PC planned to receive first-line hormono therapy",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Group 3","Patients with recurrent\u002Fprogressive\u002Fmetastatic CRPC planned to receive chemotherapy",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"Group Exo","Patients with a known or suspected diagnosis of PC or at any stage of the disease and irrespective of the treatment undergoing an imaging investigation.",[13],{"label":35,"type":10,"description":36,"interventionNames":37},"Group Bio","Patients with a known or suspected diagnosis of PC at any stage of the disease and irrespective of the treatment undergoing a tumour sampling.",[13],[39],{"type":6,"name":40,"description":41,"armGroupLabels":42,"otherNames":10},"biological samples collection and analysis","Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule",[9,19,15,23,27,35,31],[44],{"name":45,"affiliation":46,"role":47},"Ricardo Pereira Mestre, MD","Oncology Institute of Southern Switzerland (IOSI)","PRINCIPAL_INVESTIGATOR",[49,53],{"name":45,"role":50,"phone":51,"phoneExt":10,"email":52},"CONTACT","+41 (0)91 811 8446","ricardo.pereiramestre@eoc.ch",{"name":54,"role":50,"phone":55,"phoneExt":10,"email":56},"Andrea Alimonti, Prof.","+41 (0)91 8210080","andrea.alimonti@ior.iosi.ch",[58],{"facility":46,"status":59,"city":60,"state":10,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"RECRUITING","Bellinzona","6500","Switzerland","CH",{"type":65,"coordinates":66},"Point",[67,68],9.01703,46.19278,{"lat":68,"lon":67},[71,74],{"name":72,"role":50,"phone":73,"phoneExt":10,"email":52},"Pereira Mestre Ricardo, MD","+41 (0)91 811 84 46",{"name":75,"role":50,"phone":76,"phoneExt":10,"email":77},"Luigi Tortola, PhD","+41 (0)91 811 96 68","luigi.tortola@eoc.ch",{"type":79,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[81],{"name":82,"class":6},"Clinical Trial Unit Ente Ospedaliero Cantonale","100317156","valid-biomarkers-in-blood-to-predict-the-response-to-therapy-in-prostate-cancer-patients-100317156",false,"NCT03408964","Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer Patients","An Exploratory proof-of Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer Patients, a Single Center Study","Inclusion Criteria:\n\nGeneral inclusion criteria (for entering all groups)\n\n* Age ≥ 18 years\n* Histological diagnosis of prostate adenocarcinoma at different stages of disease (see Section 6.2) for which a treatment is indicated\n* Written Informed Consent\n\nInclusion criterion only for entering Group 0\n\n• Patients with a known diagnosis of CSPC or CRPC\n\nInclusion criterion only for entering Group 1a\n\n• Patients that underwent biopsies for a suspect of PC, but resulted negative for cancer\n\nExclusion Criteria:\n\nGeneral exclusion criteria (for entering all groups)\n\n* Active infection requiring treatment\n* Decrease of general condition\n* Concomitant severe comorbities\n* Difficult socioeconomic conditions making regular follow up unfeasible.\n* Need of concomitant steroids at study entry and during the study\n* Diagnosis of second tumor in the previous 5 years\n\nExclusion criterion only for entering Group 0\n\n• No antibiotic treatments in the previous 2 months before enrollment\n\nExclusion criteria only for entering Group 1\n\n* Previous radical surgery and \u002F or radical radiotherapy\n* Previous hormonal treatments\n\nExclusion criteria only for entering Group 2\n\n* No antibiotic treatments in the previous 2 months before enrollment (only in patients enrolling also for metagenomics and metabolomics)\n* Previous hormonal treatments for advanced disease\n\nExclusion criterion only for entering Group 3\n\n• No antibiotic treatments in the previous 2 months before enrollment (only in patients enrolling also for metagenomics and metabolomics analyses)","MALE","18 Years",{"count":93,"type":94},600,"ESTIMATED","OBSERVATIONAL","Participants to the study will be assigned to 7 cohorts according to the stage of disease and planned antitumor treatment at time of study entry.\n\nIn all patients, 12 ml of blood sample will be collected in EDTA tube for analysis of biological biomarkers in different time points.",[98],"Prostate Cancer","2025-11-14",{"date":101,"type":102},"2025-11-18","ACTUAL",{"date":104,"type":102},"2017-12-15",{"date":106,"type":94},"2028-12-31",{"name":5,"class":6},1]